Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has transferred all Japanese commercial rights for Panaldine, a popular blood clot treatment in Japan, to Sanofi-Aventis.
Subscribe to our email newsletter
<p>The transfer will be implemented in conformity with local regulatory requirements and the transfer is expected to occur by October 1, 2007.<br /><br />Given their long-standing relationship, both parties agreed to collaborate in the future areas of marketing and distribution in the country. Daiichi is Japan's second biggest drugmaker and it promotes Plavix, the best selling blood thinner, with Sanofi in Japan.<br /><br />Plavix won Japanese approval to treat clots in blood vessels that lead to the brain in May 2006.</p>